Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss

Regeneron said its newly approved gene therapy Otarmeni for a rare genetic form of hearing loss will be available for free in the U.S. The company has not yet set an overseas price, leaving international monetization uncertain. The approval and free U.S. access are positive for patient access and brand perception, though the immediate financial impact appears limited.

Analysis

Regeneron said its newly approved gene therapy Otarmeni for a rare genetic form of hearing loss will be available for free in the U.S. The company has not yet set an overseas price, leaving international monetization uncertain. The approval and free U.S. access are positive for patient access and brand perception, though the immediate financial impact appears limited.